Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Dose schedule of recombinant murine thrombopoietin prior to myelosuppressive and myeloablative therapy in mice
Autore:
Stefanich, EG; Carlson-Zermeno, C; McEvoy, K; Reich, M; Fielder, PJ;
Indirizzi:
Genentech Inc, S San Francisco, CA 94080 USA Genentech Inc S San Francisco CA USA 94080 S San Francisco, CA 94080 USA
Titolo Testata:
CANCER CHEMOTHERAPY AND PHARMACOLOGY
fascicolo: 1, volume: 47, anno: 2001,
pagine: 70 - 77
SICI:
0344-5704(200101)47:1<70:DSORMT>2.0.ZU;2-8
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN MEGAKARYOCYTE GROWTH; COLONY-STIMULATING FACTOR; BONE-MARROW TRANSPLANTATION; C-MPL LIGAND; GRANULOCYTE-MACROPHAGE; PROGENITOR CELLS; RHESUS-MONKEYS; HEMATOPOIETIC RECONSTITUTION; ACCELERATES PLATELET; NONHUMAN-PRIMATES;
Keywords:
thrombopoietin; platelets; myelosuppression; myeloablation; megakaryocytopoiesis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
37
Recensione:
Indirizzi per estratti:
Indirizzo: Stefanich, EG Genentech Inc, 1 DNA Way,MS 70, S San Francisco, CA 94080 USA Genentech Inc 1 DNA Way,MS 70 S San Francisco CA USA 94080 A
Citazione:
E.G. Stefanich et al., "Dose schedule of recombinant murine thrombopoietin prior to myelosuppressive and myeloablative therapy in mice", CANC CHEMOT, 47(1), 2001, pp. 70-77

Abstract

Purpose: Thrombopoietin is being investigated as a therapeutic agent for platelet recovery following myelosuppressive therapy. Little information is available, however, on the optimal dose of this drug or the timing of its administration. To develop these data, a series of studies were conducted toexamine the effects that time of dosing has on the efficacy and safety of recombinant full-length murine thrombopoietin in murine myelosuppression and murine myeloablation models. Methods: For the myelosuppression model, mice were exposed to 500 rad whole-body irradiation in a cesium irradiator andreceived an intraperitoneal dose of 1.2 mg carboplatin at time 0. For the myeloablation model, mice were exposed to 900 to 950 rad of whole-body irradiation at time 0. Results: Significant increases in the number of platelets and red and white blood cells were observed by day 10 in mice that had received a single intravenous bolus dose of recombinant murine thrombopoietinfrom 2 h before until 4 h after myelosuppressive therapy compared to thosehad received myelosuppressive therapy alone. In the myeloablation studies,mice treated with 900 rad of whole-body irradiation alone had a mortality rate of 50% compared to 0% for mice that had received recombinant murine thrombopoietin 2 h prior to whole-body irradiation. When the whole-body irradiation dose was increased to 950 rad, the mortality rate of the control mice was 83% compared to 25% for mice that had received recombinant murine thrombopoietin 2 h prior to whole-body irradiation. Dosing with recombinant murine thrombopoietin 7 days prior to whole-body irradiation resulted in a mortality rate greater than or equal to that of control mice. Conclusions: These data suggest that pretreatment with thrombopoietin can dramatically affect recovery from myelosuppressive and myeloablative therapy. Therefore, the timing of thrombopoietin administration in relation to the therapy may becritical to the drug's safety and efficacy.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/01/20 alle ore 06:38:58